Abstract
A recent clinical trial (Clinical Trial: NCT04315948) by Florence Ader et al., published on the preprint server medRxiv (Posted April 12, 2022), reported that RDV was not associated with clinical improvement at day 15 or day 29, nor with a reduction in mortality, nor with a reduction in SARS-CoV-2 RNA. In cell culture studies with SARS-CoV-2 infection in a variety of cell types, the antiviral effect of RDV was satisfactory. However, the authors of this clinical trial state that the efficacy of the drug and its toxicity in humans is over predicted. However, we came up with our own evaluation from our most relevant experimental results.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Medical – Clinical Research & Reviews
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
